Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) EPS (Basic) (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of EPS (Basic) data on record, last reported at -$0.52 in Q1 2026.

  • On a quarterly basis, EPS (Basic) fell 44.44% to -$0.52 in Q1 2026 year-over-year; TTM through Mar 2026 was -$2.03, a 6.84% decrease, with the full-year FY2025 number at -$1.87, up 15.0% from a year prior.
  • EPS (Basic) reached -$0.52 in Q1 2026 per OLMA's latest filing, down from -$0.51 in the prior quarter.
  • Over the last five years, EPS (Basic) for OLMA hit a ceiling of -$0.36 in Q1 2025 and a floor of -$0.82 in Q2 2022.
  • A 5-year average of -$0.54 and a median of -$0.52 in 2026 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): tumbled 95.24% in 2022, then skyrocketed 40.24% in 2023.
  • Tracing OLMA's EPS (Basic) over 5 years: stood at -$0.65 in 2022, then increased by 26.15% to -$0.48 in 2023, then rose by 16.67% to -$0.4 in 2024, then decreased by 27.5% to -$0.51 in 2025, then dropped by 1.96% to -$0.52 in 2026.
  • Business Quant data shows EPS (Basic) for OLMA at -$0.52 in Q1 2026, -$0.51 in Q4 2025, and -$0.49 in Q3 2025.